VEGF-A and IP-10 might be involved with the angiogenic and antiangiogenic process in CCH patients, which provides new insight into the pathophysiology of CCH and could be potential targets for treatment. This evidence concerns the gene VEGFA and columnar cell hyperplasia of the breast.